Statistical Review and Evaluation of Paliperidone for Use in Pediatric Populations Diagnosed With Schizophrenia
October 8, 2010 The U.S. Food and Drug Administration (FDA) had approved the use of Invega for adults with schizophrenia in 2006. The FDA has recently approved Invega, an atypical antipsychotic, for use by adolescents between the age of 12- and 17-years old diagnosed with schizophrenia. Download the Report . . .
